Literature DB >> 12063175

Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes.

Toshiyuki Ishibashi1, Kenji Nagata, Hiroshi Ohkawara, Takayuki Sakamoto, Keiko Yokoyama, Joji Shindo, Koichi Sugimoto, Sotaro Sakurada, Yoh Takuwa, Tamio Teramoto, Yukio Maruyama.   

Abstract

Increased production of plasminogen activator inhibitor-1 (PAI-1) in plaques plays a role in the pathogenesis of atherosclerosis. This study was conducted to investigate the effect of blockade of Rho/Rho-kinase signaling on the synthesis of PAI-1 in cultured human peripheral blood monocytes. HMG-CoA reductase inhibitors (statins) and inhibitors of Rho and Rho-kinase were added to monocyte cultures. The levels of PAI antigen and mRNA were determined by Western blotting and RT-PCR, respectively, and PAI-1 expression was assessed by immunohistochemistry. We performed pull-down assays to determine the activity of Rho by measuring the GTP-bound form of Rho A. In unstimulated and lipopolysaccharide (LPS)-stimulated cultured monocytes, statins reduced the levels of PAI-1 antigen and mRNA. The suppressive effects of statins on PAI-1 synthesis were reversed by geranylgeranylpyrophosphate (GGPP) and were mimicked by C3 exoenzyme. Immunohistochemistry confirmed the role of lipid modification by GGPP in suppressive effect of statins in PAI-1 synthesis. Pull-down assays demonstrated that statins decreased the levels of the GTP-bound form of Rho A. Our findings suggest that statins decrease the activity of Rho by inhibiting geranylgeranylation. Moreover, Rho-kinase inhibitors, Y-27632 and fasudil, suppressed the synthesis of PAI-1 in this culture system. We show that inhibition of Rho/Rho-kinase signaling downregulates the synthesis of PAI-1 in human monocytes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063175     DOI: 10.1016/s0167-4889(02)00201-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

Review 1.  Statins for community-acquired pneumonia: current state of the science.

Authors:  D Viasus; C Garcia-Vidal; F Gudiol; J Carratalà
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-27       Impact factor: 3.267

2.  Statins as first-line therapy for acute coronary syndrome?

Authors:  Petr Ostadal
Journal:  Exp Clin Cardiol       Date:  2012

3.  Statins in the first-line therapy of acute coronary syndrome - similar to aspirin?

Authors:  Petr Ostadal; David Alan; Jiri Vejvoda
Journal:  Exp Clin Cardiol       Date:  2005

Review 4.  Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.

Authors:  Robert Krysiak; Boguslaw Okopień; Zbigniew Herman
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event.

Authors:  Ron Rawlings; Anju Nohria; Ping-Yen Liu; Jason Donnelly; Mark A Creager; Peter Ganz; Andrew Selwyn; James K Liao
Journal:  Am J Cardiol       Date:  2008-12-25       Impact factor: 2.778

6.  Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes.

Authors:  Kazutaka Sakamoto; Makoto Osaki; Akira Hozumi; Hisataka Goto; Tatsuya Fukushima; Hideo Baba; Hiroyuki Shindo
Journal:  BMC Musculoskelet Disord       Date:  2011-04-27       Impact factor: 2.362

7.  Pleiotropic vasoprotective effects of statins: the chicken or the egg?

Authors:  Dimitrios Kirmizis; Dimitrios Chatzidimitriou
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.